CIK 0001635077 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Aclarion, Inc.
Sign in to watch- Ticker
- ACON
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473324725
- Phone
- 833 275 2266
- Business address
- 8181 ARISTA PLACE, STE 100, BROOMFIELD, CO, 80021
- Former names
- Nocimed, Inc.
Securities
- ACON Common Stock Nasdaq
- ACONW Warrant Nasdaq
- Open-market buys, last 90 days
- $15,990
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$15,990. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-02 | Gould Gregory A CFO | Grant or award · Stock Option (right to buy) | +17,000 | 17,000 | ||
| 2023-03-28 | Thramann Jeffrey John Executive Chairman | Other disposition | −1 | $1,000.00 | $1K | 0 |
| 2023-02-16 | Thramann Jeffrey John Executive Chairman | Purchase | +1 | $1,000.00 | $1K | 1 |
| 2022-12-29 | Ness Brent Chief Executive Officer | Purchase | +8,500 | $0.51 | $4K | 11,789 |
| 2022-12-29 | Ness Brent Chief Executive Officer | Purchase | +7,711 | $0.58 | $4K | 19,500 |
| 2022-12-29 | Lorbiecki John Paul Chief Financial Officer | Purchase | +4,100 | $0.43 | $2K | 4,100 |
| 2022-12-29 | Lorbiecki John Paul Chief Financial Officer | Purchase | +18,304.44 | $0.45 | $8K | 22,404.41 |
| 2022-12-29 | Wesemann William Director | Grant or award · Stock option (right to buy) | +63,000 | 63,000 | ||
| 2022-12-28 | Ness Brent Chief Executive Officer | Purchase | +2,289 | $0.42 | $961 | 3,289 |
| 2022-12-02 | Neal David K Director | Other acquisition | +152,128 | 186,528 | ||
| 2022-12-02 | SC Capital 1 LLC Former 10% Owner | Other disposition | −1,091,894 | 0 | ||
| 2022-12-02 | Neal David K Director | Other disposition | −152,128 | 186,528 | ||
| 2022-09-15 | Thramann Jeffrey John Executive Chairman | Grant or award · Options for Common Stock (right to buy) | +185,285 | 1,390,104 | ||
| 2022-09-15 | Ness Brent Chief Executive Officer | Grant or award · Options for Common Stock (right to buy) | +75,582 | 416,947 | ||
| 2022-09-15 | Lorbiecki John Paul Chief Financial Officer | Grant or award · Options for Common Stock (right to buy) | +16,455 | 83,389 | ||
| 2022-04-22 | Bond Ryan Chief Strategy Officer | Purchase | +20,000 | $2.80 | $56K | 20,000 |
| 2022-04-22 | Bond Ryan Chief Strategy Officer | Purchase · Warrants for Common Stock (right to buy) | +21,000 | $0.73 | $15K | 48,527 |
| 2022-04-22 | Sequira Amanda Mae Director | Grant or award · Stock option (right to buy) | +63,000 | 63,000 | ||
| 2022-04-22 | Deitsch Stephen Director | Grant or award · Stock option (right to buy) | +63,000 | 63,000 | ||
| 2022-04-22 | Breidbart Scott Director | Grant or award · Stock option (right to buy) | +63,000 | 63,000 |
Page 2 of 3 · 46 trades